VTN and myasthenia gravis: Factor B and properdin, which are complement proteins specifically involved in the alternative pathway [29,30], showed similar concentrations among AChR-MG and MuSK-MG patients, and controls (Figure 1), suggesting that C2 and C5 consumption in AChR-MG patients may be mainly a result of activation of the classical pathway.